0000000000048341

AUTHOR

Andres F. Lasave

0000-0002-9602-9769

showing 4 related works from this author

INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY

2017

PURPOSE To evaluate the effects of intravitreal bevacizumab (IVB) on retinal neovascularization in patients with proliferative diabetic retinopathy (PDR). METHODS Retrospective multicenter interventional case series. A chart review was performed of 81 consecutive patients (97 eyes) with retinal neovascularization due to PDR, who received at least 1 IVB injection. RESULTS The mean age of the patients was 55.6 ± 11.6 years. The mean number of IVB injections was 4 ± 2.5 injections (range, 1-8 injections) per eye. The mean interval between IVB applications was 3 ± 7 months. The mean duration of follow-up was 29.6 ± 2 months (range, 24-30 months). Best-corrected visual acuity and optical coheren…

0301 basic medicinemedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabmedicine.medical_treatmentVitrectomy03 medical and health sciences0302 clinical medicineOphthalmologymedicineAdverse effectRetinabusiness.industryRetrospective cohort studyGeneral MedicineDiabetic retinopathymedicine.diseaseeye diseasesOphthalmology030104 developmental biologymedicine.anatomical_structureVitreous hemorrhage030221 ophthalmology & optometrysense organsmedicine.symptombusinessmedicine.drugRetina
researchProduct

Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular ede…

2013

To evaluate the anatomical and functional outcomes at 24 months in patients with diffuse diabetic macular edema treated with primary intravitreal bevacizumab (IVB) plus grid laser photocoagulation (GLP) or primary IVB alone or GLP alone.Retrospective, interventional, comparative, multicenter study. We included in this analysis 141 eyes of 120 patients with diffuse diabetic macular edema treated with primary IVB alone (Group A), 120 eyes of 94 patients with GLP therapy (Group B), and 157 eyes of 104 patients treated with IVB plus GLP (Group C).In all 3 groups, the authors observed improvement of Early Treatment Diabetic Retinopathy Study best-corrected visual acuity from baseline to 24-month…

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresDiabetic macular edemaVisual AcuityAngiogenesis InhibitorsAntibodies Monoclonal HumanizedMacular EdemaOphthalmologymedicineHumansIn patientIntravitreal bevacizumabRetrospective StudiesRetinaDiabetic RetinopathyLaser Coagulationbusiness.industryGeneral MedicineMiddle AgedCombined Modality Therapyeye diseasesbody regionsBevacizumabOphthalmologymedicine.anatomical_structureTreatment OutcomeIntravitreal InjectionsFemalesense organsbusinessTomography Optical CoherenceRetina (Philadelphia, Pa.)
researchProduct

Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months.

2009

Purpose To report the anatomic and functional outcomes of intravitreal clindamycin and dexamethasone for the treatment of zone 1 toxoplasmic retinochoroiditis (TRC). Patients had 1 or more of the following indications for local therapy: intolerance to oral medication, contraindication to oral medication because of pregnancy, lack of response despite oral antimicrobial treatment, or treatment with concomitant oral and local therapy to avoid or limit foveal or optic disc involvement. Design Noncomparative, retrospective, multicentric interventional case series. Participants We reviewed the medical records of 12 consecutive patients (eyes) with posterior pole (zone 1) TRC who were treated week…

AdultMalemedicine.medical_specialtyVisual acuitygenetic structuresEye diseasePosterior poleAntiprotozoal AgentsVisual AcuityDexamethasoneInjectionsYoung AdultPregnancymedicineHumansFluorescein AngiographyToxoplasmosis OcularContraindicationGlucocorticoidsAntibacterial agentRetrospective Studiesmedicine.diagnostic_testbusiness.industryClindamycinDiabetic retinopathyMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesSurgeryVitreous BodyOphthalmologyTreatment OutcomeChorioretinitisPregnancy Complications ParasiticDrug Therapy CombinationFemalesense organsmedicine.symptombusinessTomography Optical CoherenceRetinopathyFollow-Up StudiesOphthalmology
researchProduct

INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retin…

2016

To report the long-term anatomical and functional outcomes of patients with choroidal neovascularization secondary to age-related macular degeneration treated with intravitreal bevacizumab (IVB).Retrospective case series. Patients diagnosed with subfoveal choroidal neovascularization secondary to age-related macular degeneration that were treated with at least 1 intravitreal injection of 1.25 mg of IVB and had a minimum follow-up of 60 months. Patients underwent best-corrected Snellen visual acuity testing, optical coherence tomography, and ophthalmoscopic examination at baseline and follow-up visits.Two hundred and forty-seven consecutive patients (292 eyes) were included. The mean number …

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyVisual acuitygenetic structuresBevacizumabVisual AcuityAngiogenesis InhibitorsOphthalmoscopy03 medical and health sciencesMacular Degeneration0302 clinical medicineOphthalmologyGeographic AtrophymedicineHumans030212 general & internal medicineFluorescein AngiographyAfliberceptAgedRetrospective StudiesAged 80 and overmedicine.diagnostic_testbusiness.industryGeneral MedicineMacular degenerationMiddle Agedmedicine.diseaseFluorescein angiographyeye diseasesChoroidal NeovascularizationBevacizumabOphthalmoscopyOphthalmologyChoroidal neovascularizationTreatment OutcomeIntravitreal Injections030221 ophthalmology & optometryFemalesense organsmedicine.symptomRanibizumabbusinessTomography Optical Coherencemedicine.drugRetina (Philadelphia, Pa.)
researchProduct